Scaling Autologous Epidermal Cell Therapies: iPSC‐Derived Keratinocytes and In Vivo Chimerism for Skin Regeneration DOI

Sina Kardeh,

Mohsen Mazloomrezaei, Ahmad Hosseini

et al.

Experimental Dermatology, Journal Year: 2025, Volume and Issue: 34(5)

Published: April 27, 2025

ABSTRACT Severe skin injuries and genetic disorders such as epidermolysis bullosa present significant clinical challenges due to limitations in current epidermal replacement therapies. While promising, cultured epithelial autografts (CEAs) suffer from prolonged culture times, cellular senescence, low‐quality outcomes, limiting their widespread application. Recent advancements iPSC‐derived keratinocytes (iKeratinocytes) vivo chimerism offer transformative potential for scalable personalised regeneration. Advances understanding transcriptional networks, mRNA delivery, CRISPR‐based genome editing, automated biomanufacturing processes can enable improved efficient protocols generating iKeratinocytes. Despite these advances, there are still scaling iKeratinocytes, including optimising xeno‐free systems developing reproducible methods multilayered with appendages. Interspecies utilising lineage‐specific ablation targeted utero delivery of organ progenitor cells human tissue development within animal hosts, offering an alternative novel platform cell generation. This method, however, requires further refinements complete detachment target the hosts integration chimeric models. Together, iKeratinocytes hold great promise advancing autologous therapies enabling broader adoption outcomes patients severe disorders.

Language: Английский

Scaling Autologous Epidermal Cell Therapies: iPSC‐Derived Keratinocytes and In Vivo Chimerism for Skin Regeneration DOI

Sina Kardeh,

Mohsen Mazloomrezaei, Ahmad Hosseini

et al.

Experimental Dermatology, Journal Year: 2025, Volume and Issue: 34(5)

Published: April 27, 2025

ABSTRACT Severe skin injuries and genetic disorders such as epidermolysis bullosa present significant clinical challenges due to limitations in current epidermal replacement therapies. While promising, cultured epithelial autografts (CEAs) suffer from prolonged culture times, cellular senescence, low‐quality outcomes, limiting their widespread application. Recent advancements iPSC‐derived keratinocytes (iKeratinocytes) vivo chimerism offer transformative potential for scalable personalised regeneration. Advances understanding transcriptional networks, mRNA delivery, CRISPR‐based genome editing, automated biomanufacturing processes can enable improved efficient protocols generating iKeratinocytes. Despite these advances, there are still scaling iKeratinocytes, including optimising xeno‐free systems developing reproducible methods multilayered with appendages. Interspecies utilising lineage‐specific ablation targeted utero delivery of organ progenitor cells human tissue development within animal hosts, offering an alternative novel platform cell generation. This method, however, requires further refinements complete detachment target the hosts integration chimeric models. Together, iKeratinocytes hold great promise advancing autologous therapies enabling broader adoption outcomes patients severe disorders.

Language: Английский

Citations

0